New antiretroviral agents: looking beyond protease and reverse transcriptase.
The clinical utility of intervention in HIV-1 disease has been proven by inhibitors targeting reverse transcriptase and protease. However, novel approaches including inhibition of viral entry, integration and assembly would provide additional options to maintain long-term suppression. The identification of specific inhibitors for each of these processes has recently validated these approaches as viable alternatives for the development of new agents to treat HIV-1 infection. The most recent preclinical advances in novel antiretroviral agents are reviewed and promising new approaches that target viral processes are highlighted.
Miller
M D
MD
Department of Biological Chemistry, Merck Research Laboratories, West Point, PA 19486, USA.
Hazuda
D J
DJ
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015195:Drug Design; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects* / Q000472:pathogenicity / Q000502:physiology; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D019065:Virus Assembly / Q000187:drug effects*; D016662:Virus Integration / Q000187:drug effects*
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors